Chemotherapy of hematological malignancies in patients with COVID-19

T. S. Chudnova; Чуднова Т. С.; E. A. Baryakh; Барях Е. А.; M. S. Litvinenko; Литвиненко М. С.; T. N. Tolstykh; Толстых Т. Н.; O. L. Kochneva; Кочнева О. Л.; E. Y. Grishina; Гришина Е. Ю.; E. N. Misyurina; Мисюрина Е. Н.; K. V. Yatskov; Яцков К. В.; E. I. Zhelnova; Желнова Е. И.; Y. Y. Polyakov; Поляков Ю. Ю.; K. V. Kaluzhskaya; Калужская К. В.

doi:10.17650/1818-8346-2022-17-2-107-120

Chemotherapy of hematological malignancies in patients with COVID-19

Authors: Chudnova T.S.¹, Baryakh E.A.¹, Litvinenko M.S.¹, Tolstykh T.N.¹, Kochneva O.L.¹, Grishina E.Y.¹, Misyurina E.N.¹, Yatskov K.V.¹, Zhelnova E.I.¹, Polyakov Y.Y.¹, Kaluzhskaya K.V.¹
Affiliations:
1. City Clinical Hospital No. 52, Moscow Healthcare Department
Issue: Vol 17, No 2 (2022)
Pages: 107-120
Section: TREATMENT OF HEMATOLOGICAL MALIGNANCIES IN PATIENTS WITH COVID-19: PRO AND CONTRA
Published: 13.04.2022
URL: https://oncohematology.abvpress.ru/ongm/article/view/543
DOI: https://doi.org/10.17650/1818-8346-2022-17-2-107-120
ID: 543

Cite item

Full Text

Abstract
About the authors
References
Supplementary files
Statistics

Abstract

In the era of COVID-19, the chemotherapy of patients with hematological malignancies has become the cornerstone in hematology. Secondary immunodeficiency as a result of hemoblastosis, predisposes to a more severe course of coronavirus infection, and specific antitumor treatment only exacerbates patients immunodeficiency. Thus, there is a problem of conducting chemotherapy during the COVID-19 pandemic. At the moment, there are no unified recommendations for risk assessment and choice of treatment for patients with oncohematological diseases and concomitant coronavirus infection. In this article, we present a series of clinical cases of patients with hematological malignancies diagnosed with coronavirus infection at the onset of a hematological disease or after chemotherapy. Patients with long-term persistent coronavirus infection requiring specific anticancer treatment were allocated to a separate group. We hope that this article will help to set a vector for further research, as well as serve as a clear example of the clinical situations that a hematologist may face during the COVID-19 pandemic.